Insulin-like growth factor receptor-1 expression predicts postoperative recurrence in adenocarcinoma of the lung

Experimental and Therapeutic Medicine

Volumn 2, Issue 4, 2011, Pages 585-590

  Nakagawa, Makoto ^a   Uramoto, Hidetaka ^a   Shimokawa, Hidehiko ^a   Onitsuka, Takamitsu ^a   Hanagiri, Takeshi ^a   Tanaka, Fumihiro ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Adenocarcinoma; Insulin like growth factor receptor 1; Lung cancer; Recurrence

Indexed keywords

CARBOPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GEMCITABINE; PACLITAXEL; SCATTER FACTOR; SOMATOMEDIN C RECEPTOR; UFT;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER SURGERY; DISEASE FREE SURVIVAL; FEMALE; GENE EXPRESSION; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; ONCOGENE K RAS; POSTOPERATIVE PERIOD; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION;

EID: 79958064122     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2011.258     Document Type: Article

References (23)

1. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005.
2. Janssen-Heijnen ML and Coebergh JW: Trends in incidence and prognosis of the histological subtypes of lung cancer in North America, Australia, New Zealand and Europe. Lung Cancer 31: 123-137, 2001.
3. Goya T, Asamura H, Yoshimura H, Kato H, Shimokata K, Tsuchiya R, Sohara Y, Miya T and Miyaoka E: The Japanese Joint Committee of Lung Cancer Registry Prognosis of 6644 resected non-small cell lung cancers in Japan: a Japanese lung cancer registry study. Lung Cancer 50: 227-234, 2005.
4. Pignon J P, Tribodet H, Scagliotti G V, et al: Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 26: 3552-3559, 2008.
5. Kato H, Ichinose Y, Ohta M, Hata E, Tsubota N, Tada H, Watanabe Y, Wada H, Tsuboi M, Hamajima N and Ohta M: Japan Lung Cancer Research Group on Postsurgical Adjuvant Chemotherapy. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 350: 1713-1721, 2004.
6. Khandwala HM, McCutcheon IE, Flyvbjerg A and Friend KE: The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 21: 215-244, 2000.
7. LeRoith D and Roberts CT Jr: The insulin-like growth factor system and cancer. Cancer Lett 195: 127-137, 2003.
8. Merrick DT, Dziadziuszko R, Szostakiewicz B, Szymanowska A, Rzyman W, Jassem E, Jassem J, Franklin WA, Bunn PA and Hirsch FR: High insulin-like growth factor 1 receptor (IGF 1R) expression is associated with poor survival in surgically treated non-small cell lung cancer (NSCLC) patients. J Clin Oncol 25: 7550, 2007.
9. Vallières E, Shepherd FA, Crowley J, van Houtte P, Postmus PE, Carney D, Chansky K, Shaikh Z and Goldstraw P: International Association for the Study of Lung Cancer International Staging Committee and Participating Institutions. The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 4: 1049-1059, 2009.
10. Onitsuka T, Uramoto H, Nose N, Takenoyama M, Hanagiri T, Sugio K and Yasumoto K: Acquired resistance to geftinib: the contribution of mechanisms other than the T790M, MET, and HGF status. Lung Cancer 68: 198-203, 2010.
11. Yamashita T, Uramoto H, Onitsuka T, Ono K, Baba T, So T, So T, Takenoyama M, Hanagiri T, Oyama T and Yasumoto K: Association between lymphangiogenesis-/micrometastasis- and adhesion-related molecules in resected stage I NSCLC. Lung Cancer 70: 320-328, 2010.
12. Chang MH, Lee J, Han J, Park YH, Ahn JS, Park K and Ahn MJ: Prognostic role of insulin-like growth factor receptor-1 expression in small cell lung cancer. APMIS 117: 861-869, 2009.
13. Onitsuka T, Uramoto H, Ono K, Takenoyama M, Hanagiri T, Oyama T, Izumi H, Kohno K and Yasumoto K: Comprehensive molecular analyses of lung adenocarcinoma with regard to the epidermal growth factor receptor, K-ras, MET, and hepatocyte growth factor status. J Thorac Oncol 5: 591-596, 2010.
14. Shimokawa H, Uramoto H, Onitsuka T, Iwata T, Nakagawa M, Ono K and Hanagiri T: TS expression predicts postoperative recurrence in adenocarcinoma of the lung. Lung Cancer: Oct. 21, 2010 (E-pub ahead of print).
15. Ludovini V, Bellezza G, Pistola L, et al: High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients. Ann Oncol 20: 842-849, 2009.
16. Uramoto H, Sugio K, Oyama T, Ono K, Sugaya M, Yoshimatsu T, Hanagiri T, Morita M and Yasumoto K: Epidermal growth factor receptor mutations are associated with geftinib sensitivity in non-small cell lung cancer in Japanese. Lung Cancer 51: 71-77, 2006.
17. Cappuzzo F, Toschi L, Tallini G, et al: Insulin-like growth factor receptor 1 (IGFR-1) is signifcantly associated with longer survival in non-small-cell lung cancer patients treated with geftinib. Ann Oncol 17: 1120-1127, 2006.
18. Karp DD, Paz-Ares LG, Novello S, et al: Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J Clin Oncol 27: 2516-2522, 2009.
19. Cappuzzo F, Tallini G, Finocchiaro G, et al: Insulin-like growth factor receptor 1 (IGF1R) expression and survival in surgically resected non-small-cell lung cancer (NSCLC) patients. Ann Oncol 21: 562-567, 2010.
20. Lee AV, Cui X and Oesterreich S: Cross-talk among estrogen receptor, epidermal growth factor, and insulin-like growth factor signaling in breast cancer. Clin Cancer Res 7: 4429-4435, 2001.
21. Gilmore AP, Valentijn AJ, Wang P, Ranger AM, Bundred N, O'Hare MJ, Wakeling A, Korsmeyer SJ and Streuli CH: Activation of BAD by therapeutic inhibition of epidermal growth factor receptor and transactivation by insulin-like growth factor receptor. J Biol Chem 277: 27643-27650, 2002.
22. Shen YM, Yang XC, Yang C and Shen JK: Enhanced therapeutic effects for human pancreatic cancer by application K-ras and IGF-IR antisense oligodeoxynucleotides. World J Gastroenterol 14: 5176-5185, 2008.
23. Scartozzi M, Mandolesi A, Giampieri R, et al: Insulin-like growth factor 1 expression correlates with clinical outcome in K-RAS wild-type colorectal cancer patients treated with cetuximab and irinotecan. Int J Cancer 127: 1941-1947, 2010.